| time 0* | time 1** | time 2*** | time 3**** | time 4***** | time 5****** |
---|
Antibodies | Jo-1 | 130 | 165 | 160 | 161 | 145 |
SSA | 114 | 110 | 105 | 103 | 100 | 100 |
PaO2, mmHg | 74 | 68 | 73 | 85 | 89 | 86 |
PaCO2, mmHg | 34 | 30 | 32 | 32 | 35 | 35 |
DLCO, % pred. | 80 | 22 | 31 | 35 | 42 | 52 |
Krogh index | 80 | 54,1 | 67 | 57 | 63 | 65 |
FVC, % pred. | 98 | 45 | 46 | 90 | 98 | 99 |
FEV1, % pred. | 90 | 50 | 52 | 80 | 90 | 90 |
6MWT, m | 600 | 75 | 150 | 450 | 500 | 500 |
sPAP, mm Hg | 35 | 35 | 35 | 33 | 33 | 32 |
- * Before treatment with rituximab. ** 1st course of rituximab administration. *** Interval between 1st and 2nd course of therapy with rituximab. **** 2nd course of rituximab administration. ***** After 2nd course of therapy with rituximab. ****** Final medical examination.
- Definitions of abbreviations: 6MWT, 6-minute walking test; DLCO, diffusing lung capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; sPAP, systolic pulmonary artery pressure.